RPS6KB1 and breast cancer: Whole-genome profiling of S6K1 and S6K2 high tumours, as well as after in vitro knock-down of the two kinases both resulted in significant differences, suggesting that isoform specific targeting of S6K1 or S6K2 may be valuable to allow further individualised breast cancer treatment regimens.